Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation

Prostate cancer is the fifth leading cause of male cancer death worldwide. Although docetaxel chemotherapy has been used for more than fifteen years to treat metastatic castration resistant prostate cancer, the high inter-individual variability of treatment efficacy and toxicity is still not well un...

Descripción completa

Detalles Bibliográficos
Autores principales: Varnai, Reka, Koskinen, Leena M., Mäntylä, Laura E., Szabo, Istvan, FitzGerald, Liesel M., Sipeky, Csilla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723793/
https://www.ncbi.nlm.nih.gov/pubmed/31398933
http://dx.doi.org/10.3390/genes10080599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723793/
https://www.ncbi.nlm.nih.gov/pubmed/31398933
http://dx.doi.org/10.3390/genes10080599

Ejemplares similares